Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators
Hilmar Weinmann
ChemMedChem (2016) Vol. 11, Iss. 5, pp. 450-466
Closed Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
Katarzyna Guzik, Krzysztof M. Zak, P. Grudnik, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 13, pp. 5857-5867
Open Access | Times Cited: 297
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
Eddy W. Yue, Richard Sparks, Padmaja Polam, et al.
ACS Medicinal Chemistry Letters (2017) Vol. 8, Iss. 5, pp. 486-491
Open Access | Times Cited: 259
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu‐Monette, Mingzhi Zhang, Jianyong Li, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 257
Smart Injectable Hydrogels for Cancer Immunotherapy
Yu Chao, Qian Chen, Zhuang Liu
Advanced Functional Materials (2019) Vol. 30, Iss. 2
Closed Access | Times Cited: 231
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Chunyong Ding, Zilan Song, Ancheng Shen, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 12, pp. 2272-2298
Open Access | Times Cited: 228
Laser Immunotherapy in Combination with Perdurable PD-1 Blocking for the Treatment of Metastatic Tumors
Lihua Luo, Chunqi Zhu, Hang Yin, et al.
ACS Nano (2018) Vol. 12, Iss. 8, pp. 7647-7662
Closed Access | Times Cited: 161
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 27
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
Katarzyna Magiera‐Mularz, Łukasz Skalniak, Krzysztof M. Zak, et al.
Angewandte Chemie International Edition (2017) Vol. 56, Iss. 44, pp. 13732-13735
Open Access | Times Cited: 149
Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
Bayard R. Huck, Lisa Kötzner, Klaus Urbahns
Angewandte Chemie International Edition (2017) Vol. 57, Iss. 16, pp. 4412-4428
Open Access | Times Cited: 133
Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
Katarzyna Guzik, Marcin D. Tomala, Damian Muszak, et al.
Molecules (2019) Vol. 24, Iss. 11, pp. 2071-2071
Open Access | Times Cited: 130
Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity against Advanced Cancer
Wenfei Chen, Zhaofei Guo, Yining Zhu, et al.
Advanced Functional Materials (2019) Vol. 30, Iss. 1
Closed Access | Times Cited: 109
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
William G. Kerr, John D. Chisholm
The Journal of Immunology (2018) Vol. 202, Iss. 1, pp. 11-19
Open Access | Times Cited: 105
Prospects for combined use of oncolytic viruses and CAR T-cells
Adam Ajina, John Maher
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 100
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Isobel Okoye, Michael Houghton, D. Lorne Tyrrell, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 91
Recent advances in small molecule based cancer immunotherapy
Binbin Cheng, Weien Yuan, Jing Su, et al.
European Journal of Medicinal Chemistry (2018) Vol. 157, pp. 582-598
Closed Access | Times Cited: 84
Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer
Xianli Hu, Bo Hou, Zhiai Xu, et al.
Advanced Science (2020) Vol. 7, Iss. 8
Open Access | Times Cited: 83
Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Quan Liu, Yanhong Duo, Jianye Fu, et al.
Nano Today (2020) Vol. 36, pp. 101023-101023
Closed Access | Times Cited: 70
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
Yubo Wang, Yuanyuan Zhou, Sheng Cao, et al.
Bioorganic Chemistry (2021) Vol. 111, pp. 104833-104833
Closed Access | Times Cited: 59
Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs
André E. Nel, Kuo‐Ching Mei, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5184-5232
Open Access | Times Cited: 45
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
Rita C. Acúrcio, Sabina Pozzi, Bárbara Carreira, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 7, pp. e004695-e004695
Open Access | Times Cited: 39
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Maryland Franklin, Suso Platero, Kamal S. Saini, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003231-e003231
Open Access | Times Cited: 38
Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
Chuan Hu, Yujun Song, Yiwei Zhang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 5, pp. 2176-2187
Open Access | Times Cited: 38
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Natalie Fuchs, Longfei Zhang, Laura Calvo‐Barreiro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 68-68
Open Access | Times Cited: 8
Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Tingkai Chen, Qi Li, Zongliang Liu, et al.
European Journal of Medicinal Chemistry (2018) Vol. 161, pp. 378-398
Closed Access | Times Cited: 80
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
Wenjie Zhai, Xiuman Zhou, Hongfei Wang, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 6, pp. 1047-1060
Open Access | Times Cited: 66
Page 1 - Next Page

Scroll to top